Table 2.

Cost inputs used in the model, modified societal perspective.^*

Variable				Cost (€)
CRC screening, per procedure		FIT				Biomarker
Organizational costs**		14.61				14.61
Test		7.29†				tbd‡
Patient time cost		15.93				15.93
Total screen costs, per person invited^		37.83				tbd
Follow-up/surveillance, per procedure
Colonoscopy, no polypectomy				447
Colonoscopy, polypectomy				584
Colonoscopy, diagnosis clinical CRC				688
Colonoscopy, complications§				3,156
CRC treatment, per patient per year||	Stage I		Stage II		Stage III		Stage IV
Initial treatment	17,219		22,177		26,585		30,992
Continuous care	685		685		685		685
Terminal care, death CRC	23,786		23,786		24,888		32,050
Terminal care, death other causes	9,352		8,912		10,234		19,930

CRC, colorectal cancer; FIT, fecal immunochemical test; tbd, to be determined.

^*For the calculation of patient time costs we assumed an average hourly wage of €15.93.²⁴ We assumed 1, 16, and 112 hours of patient time per procedure for FIT and biomarker testing, colonoscopy (including bowel preparation), and colonoscopy complications respectively. For CRC treatment we assumed 244, 19, and 283 hours of patient time per year of care in initial treatment, continuous care, and terminal care respectively. ^{25, 26}

^**Organizational costs for screening were based on the Dutch cervical cancer screening program, adjusted for differences with FIT screening, and include costs for administration, education and quality assurance.

^†Includes €2.48 for test kit and €4.81 for analysis.

^‡The unit cost of the biomarker test variants (test kit and analysis of the test) was determined in the threshold analysis.

^§Cost per complication. We assumed a complication rate of 2.4 per 1,000 colonoscopies

^||CRC treatments were divided into three clinically relevant phases: initial, continuous, and terminal care. The initial phase was defined as the first 12 months following diagnosis, the terminal phase was defined as the final 12 months of life, and the continuous phase was defined as all months between the initial and terminal phase. For patients surviving less than 24 months, the final 12 months were allocated to the terminal phase. The remaining months of observation were allocated to the initial phase.

^{^}For non-attenders (sensitivity analysis) the test-analyses and patient cost were not applied